In the preceding three months, 23 analysts have released ratings for Eli Lilly and Co LLY, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 16 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 5 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 10 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Eli Lilly and Co, presenting an average target of $833.91, a high estimate of $1000.00, and a low estimate of $630.00. Marking an increase of 14.42%, the current average surpasses the previous average price target of $728.79.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Eli Lilly and Co among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $892.00 | $850.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $885.00 | $815.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $723.00 | $650.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Andrew Baum | Citigroup | Raises | Buy | $895.00 | $675.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $850.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $850.00 | $775.00 |
| Geoff Meacham | B of A Securities | Raises | Buy | $1000.00 | $800.00 |
| Elmar Kraus | DZ Bank | Announces | Hold | $820.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $950.00 | $805.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Robyn Karnauskas | Truist Securities | Raises | Buy | $850.00 | $650.00 |
| David Phung | Morgan Stanley | Raises | Overweight | $805.00 | $763.00 |
| Geoff Meacham | Barclays | Raises | Overweight | $810.00 | $680.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $825.00 | $700.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $865.00 | $710.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $825.00 | $700.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $815.00 | $630.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $630.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly and Co. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly and Co compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Eli Lilly and Co's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Eli Lilly and Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Eli Lilly and Co analyst ratings.
All You Need to Know About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Co's Economic Impact: An Analysis
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Eli Lilly and Co displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 28.1%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Eli Lilly and Co's net margin excels beyond industry benchmarks, reaching 23.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly and Co's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 19.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Eli Lilly and Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: Eli Lilly and Co's debt-to-equity ratio is below the industry average at 2.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
